Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
11
2020
accepted:
18
01
2021
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
12
2
2021
Statut:
epublish
Résumé
Airborne transmission is predicted to be a prevalent route of human exposure with SARS-CoV-2. Aside from African green monkeys, nonhuman primate models that replicate airborne transmission of SARS-CoV-2 have not been investigated. A comparative evaluation of COVID-19 in African green monkeys, rhesus macaques, and cynomolgus macaques following airborne exposure to SARS-CoV-2 was performed to determine critical disease parameters associated with disease progression, and establish correlations between primate and human COVID-19. Respiratory abnormalities and viral shedding were noted for all animals, indicating successful infection. Cynomolgus macaques developed fever, and thrombocytopenia was measured for African green monkeys and rhesus macaques. Type II pneumocyte hyperplasia and alveolar fibrosis were more frequently observed in lung tissue from cynomolgus macaques and African green monkeys. The data indicate that, in addition to African green monkeys, macaques can be successfully infected by airborne SARS-CoV-2, providing viable macaque natural transmission models for medical countermeasure evaluation.
Identifiants
pubmed: 33529233
doi: 10.1371/journal.pone.0246366
pii: PONE-D-20-35005
pmc: PMC7853502
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246366Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14857-14863
pubmed: 32527856
Hum Genomics. 2020 May 12;14(1):17
pubmed: 32398162
Syst Biol. 2003 Oct;52(5):696-704
pubmed: 14530136
Occup Med (Lond). 2020 Jul 17;70(5):297-299
pubmed: 32476011
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
Emerg Infect Dis. 2020 Jun;26(6):1320-1323
pubmed: 32125269
PLoS Pathog. 2020 Nov 12;16(11):e1008949
pubmed: 33180882
Signal Transduct Target Ther. 2020 Oct 19;5(1):157
pubmed: 32814760
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Nat Methods. 2012 Jul 30;9(8):772
pubmed: 22847109
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32379723
Nat Immunol. 2021 Jan;22(1):86-98
pubmed: 33235385
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Virol Methods. 2019 Aug;270:12-17
pubmed: 30998959
PLoS Pathog. 2020 Sep 18;16(9):e1008903
pubmed: 32946524
Int J Environ Res Public Health. 2020 Apr 23;17(8):
pubmed: 32340347
bioRxiv. 2020 May 14;:
pubmed: 32511338
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Br J Haematol. 2020 Jul;190(2):179-184
pubmed: 32453877
Environ Int. 2020 Sep;142:105832
pubmed: 32521345